Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RVX-sCPD9 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Healthy adults will receive a single dose of 1x10\^2 FFU RVX-sCPD9 vaccine. It will be administered intranasally through a nasal atomization device with a spray divider to provide 0.25mL in each nostril. 3 sentinel participants, under 50 years of age, will be enrolled first and then the reminder. N= 20 |
| Arm 2 | EXPERIMENTAL | Healthy adults will receive a single dose of 1x10\^3 FFU RVX-sCPD9 vaccine. It will be administered intranasally through a nasal atomization device with a spray divider to provide 0.25mL in each nostril. 3 sentinel participants, under 50 years of age, will be enrolled first and then the reminder. N= 20 |
| Arm 3 | EXPERIMENTAL | Healthy adults will receive a single dose of 1x10\^4 FFU RVX-sCPD9 vaccine. It will be administered intranasally through a nasal atomization device with a spray divider to provide 0.25mL in each nostril. 3 sentinel participants, under 50 years of age, will be enrolled first and then the reminder. N= 20 |
| Arm 4 | EXPERIMENTAL | Healthy adults will receive a single dose of 5x10\^4 FFU RVX-sCPD9 vaccine. It will be administered intranasally through a nasal atomization device with a spray divider to provide 0.25mL in each nostril. 3 sentinel participants, under 50 years of age, will be enrolled first and then the reminder. N= 20 |
| Name | Type | Description |
|---|---|---|
| RVX-sCPD9 | BIOLOGICAL | RVX-sCPD9 is a live-attenuated SARS-CoV-2 vaccine candidate engineered from the ancestral B.1 strain for intranasal administration to prevent coronavirus disease 2019 (COVID-19) and reduce viral transmission. The vaccine was generated through two complementary attenuation strategies: a codon-pair-deoptimization of the viral genome that reduced viral fitness while preserving protein amino acid sequence, and a deletion of the spike furin cleavage site (FCS), a modification known to prevent horizontal transmission and further attenuate pathogenicity. |
Inclusion Criteria: 1. Provides written informed consent before initiation of any study procedures. 2. Able to understand and agree to comply with planned study procedures and be available for all study visits. 3. Non-pregnant adults, 18 through 64 years of age at the time of study product administ...
RVX-sCPD9 is an investigational monoclonal antibody being developed for COVID-19. It is currently in Phase 1 clinical development as a booster intranasal COVID-19 vaccine. The drug is being studied for its safety, reactogenicity, and immunogenicity in healthy volunteers.
RVX-sCPD9 is being developed by National Healthcare Corp., a company listed on the stock exchange under the ticker NHC. The company is conducting a Phase 1 clinical trial of the drug in the United States.
RVX-sCPD9 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is designed to evaluate the safety, reactogenicity, and immunogenicity of the drug as a booster intranasal COVID-19 vaccine.
RVX-sCPD9 is being evaluated in a single Phase 1 clinical trial with the identifier NCT07703475. The trial is titled "A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine" and is planned to enroll 80 participants in the United States. The trial is not yet recruiting.
RVX-sCPD9 is administered as an intranasal vaccine. The Phase 1 clinical trial is studying the drug as a booster dose for COVID-19. The trial is controlled but not randomized or double-blinded, and it enrolls healthy volunteers aged 18 years and older.